Biosimilars and Heterogeneous Technological Trajectories in the Argentine Biopharmaceutical Industry.

This paper will review the strategies and learning trajectories followed to tap the opportunities opened by the successive waves of biotechnologies: early imitators followed by late imitators in the first generation of biosimilars (erythropoietin, insulins, interferons), and then sequential entry and skipping stages during the second generation (monoclonal antibodies). [ABSTRACT FROM AUTHOR]